Evaluation of Clinical Judgement at Initiation of AML-Therapy in Elderly Patients - A Prospective Randomized Trial.

Ulrich S. Schuler(University Hospital Carl Gustav Carus), Gerhard Ehninger(University Hospital Carl Gustav Carus), H. Bodenstein(Pius Hospital Oldenburg), Regina Herbst(Klinikum Chemnitz), Mathias Hänel(Klinikum Chemnitz), Ulrich Kaiser(University of Applied Sciences Landshut), Thomas Wagner, Hannes Wandt(Nuremberg Hospital), Norbert Schmitz(University Hospital Münster), Karl-Heinz Pflueger, Hermann Einsele(Universitätsklinikum Würzburg)
Blood
November 16, 2007
10.1182/blood.v110.11.2863.2863
Cited by 1

Related Papers

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
|Blood|2007|971